| Ytd | -40.62% | |
| 1y | 21.34% |
| Open | 18.95 | Prev Close | 18.37 | Low | 18.43 | High | 19.34 | Mkt Cap | 2.04B |
| Vol | 3.18M | Avg Vol | 2.89M | EPS | -3.35 | P/E | N/A | Forward P/E | -7.23 |
| Beta | 0.90 | Short Ratio | 8.97 | Inst. Own | 111.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 16.36 | 200-d Avg | 24.10 | 1yr Est | 35.50 |
VRDN News
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expa
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform a
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and r
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen'
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raise
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Thera
Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch
U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, follo
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and main
U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutic
First approved treatment for thyroid eye disease (TED) with labeling that includes data for both act
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company